2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 388-390
Technology and Procedures, Cell Expansion, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Gene Therapy, Biological Processes, Hematopoiesis, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, VWD, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

949 First clinical Results of Precise HBB Gene correction by homology-directed repair in patients with severe sickle cell disease: Safety and efficacy from phase 1A of the RESTORE Study

John F. DiPersio, MD, David Shyr, MD2, Hemalatha Geetharani Rangarajan I, MD3, Ashley Gray, MD4, Zachary D. Crees, MD5, Jaap Jan Boelens, MD, PhD6, Markus Y. Mapara, MD PhD7, May Chien, MD8, Robert Lowsky, MD9, Maggie Nash10, Anthony Villella, MD11, Vivien A Sheehan, MD,PhD12, Jenni Herber13, Tirzah Williams14, Edina Poletto, PhD15, Dana Duan, PhD16, Jason Skowronski17, Angel Yuan18, DeAngela Purnell19, Alisha Bouge20, Valentin Barsan, MD21, Annalisa Lattanzi22, Matthew Hebden Porteus, MD, PhD23
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Stanford University, Stanford, California, United States
3 Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, Ohio, United States
4 Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Columbia University Irving Medical Center, New York, New York, United States
8 Stanford University, Stanford, California, United States
9 Stanford University, Stanford, California, United States
10 Washington University School of Medicine, St. Louis, Missouri, United States
11 Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, Ohio, United States
12 Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia, United States
13 Kamau Therapeutics, South San Francisco, California, United States
14 Kamau Therapeutics, South San Francisco, California, United States
15 Kamau Therapeutics, South San Francisco, California, United States
16 Kamau Therapeutics, South San Francisco, California, United States
17 Kamau Therapeutics, South San Francisco, California, United States
18 Kamau Therapeutics, South San Francisco, California, United States
19 Kamau Therapeutics, South San Francisco, California, United States
20 Kamau Therapeutics, South San Francisco, California, United States
21 Kamau Therapeutics, South San Francisco, California, United States
22 Kamau Therapeutics, South San Francisco, California, United States
23 Kamau Therapeutics, South San Francisco, California, United States

Background 

Current gene-editing therapies for sickle cell disease (SCD) primarily achieve clinical benefit through fetal hemoglobin upregulation. Nulabeglogene autogedtemcel (nula-cel) is a differentiated autologous hematopoietic stem and progenitor cell (HSPC) therapy that uses CRISPR-Cas9-mediated homology-directed repair (HDR) to precisely correct the sickle mutation in the endogenous HBB gene, with the goal of restoring physiologic adult hemoglobin (HbA) expression. We report the first clinical results from the sentinel cohort of the ongoing Phase 1/2 RESTORE study (NCT04819841) using a revised manufacturing process (V2.0) for nula-cel. 

Methods 

Adults (18-50 years old) with severe SCD underwent mobilization and collection of autologous CD34+ HSPCs followed by ex vivo CRISPR-Cas9-mediated homology directed repair (HDR) gene correction using a recombinant AAV donor template. Following myeloablative busulfan conditioning, patients received a single infusion of nula-cel. Safety, hematopoietic recovery, molecular correction, hemoglobin composition, clinical outcomes, and exploratory erythrocyte phenotyping were evaluated. 

Results 

The first patient treated with nula-cel was infused 4 years ago using a V1.0 manufacturing process and remains clinically well, transfusion and growth factor free, and has had no vaso-occlusive events since infusion. We now report outcomes for the three patients who successfully underwent manufacturing and infusion of V2.0 nula-cel in the sentinel cohort for the Phase 1/2 trial. Mobilization required a median of 1.3 apheresis cycles (1, 1, 3) to achieve the target cell dose (range 7.3-10.2 x 106 CD34+ cells/kg). Drug product HDR allele frequencies met target (>20%) in all three patients with a range of 32%-38%. Neutrophil engraftment was prompt in all three patients [day (D)19, D21 and D32], and all became transfusion independent prior to hospital discharge.  For the two patients with >6 months of follow-up the hematologic outcomes have met target efficacy specifications with the total hemoglobin above 10 g/dL (10.2 and 11.1) with normal platelet and neutrophil counts.  Hemoglobin electrophoresis showed the desired mechanism of action with a low HbS (17.6% at 12 months and 19.1% at 8 months) and high total HbA (76.8% at 12 months and 66.8% at 8 months). The ratio of non-S to HbS is >4 for both evaluable patients. Bone marrow and myeloid HDR allele frequencies stabilized at approximately 20% (last available 20.9% at 9 months and 17.7% at 6 months) consistent with durable engraftment of gene-corrected HSPCs. In addition, analysis of editing outcomes shows a diverse, polyclonal multilineage hematopoietic reconstitution. LDH, a marker of hemolysis, is within normal limits. Exploratory single-cell analyses demonstrated that >90% of circulating erythrocytes contained protective levels of anti-sickling hemoglobin. No vaso-occlusive events occurred following nula-cel infusion. The third patient is at month 1.5 at the time of abstract submission and is too early in follow-up to report on efficacy outcomes. No serious adverse events related to nula-cel or the gene-editing procedure were observed. Adverse events were consistent with myeloablative busulfan conditioning and autologous hematopoietic stem-cell transplantation. Protocol-specified analyses demonstrated low and unchanged levels of off-target editing. 

Conclusions 

These initial clinical results using an improved manufacturing process (V2.0) demonstrate that precise HDR-mediated correction of the endogenous HBB gene is feasible and associated with durable engraftment of gene-corrected HSPCs, physiologic adult hemoglobin production, suppression of sickle hemoglobin, transfusion independence, and elimination of vaso-occlusive events with no product-related adverse events. These findings support continued clinical evaluation of precise HBB gene correction as a potentially transformative therapeutic strategy for SCD. 

John F. DiPersio, MD: Magenta Therapeutics, Wugen/Allotera Therapeutics - Patents & Royalties; Vertex Pharmaceuticals, Genetix, SPARC - Consultancy (Includes expert testimony)